Macquarie Group LTD Alnylam Pharmaceuticals, Inc. Transaction History

Macquarie Group LTD

$85.1 Billion
Q2 2024

A detailed history of Macquarie Group LTD transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 59,455 shares of ALNY stock, worth $16.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

59,455

Previous 55,907 6.35%

Holding current value

$16.3 Million

Previous $8.36 Million 72.91%

% of portfolio

0.02%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$143.31 - $247.0 $508,463 - $876,356	3,548 Added 6.35%	59,455 $14.4 Million
Q1 2024 May 14, 2024	BUY	$146.51 - $198.2 $1.3 Million - $1.76 Million	8,890 Added 18.91%	55,907 $8.36 Million
Q4 2023 Feb 14, 2024	BUY	$151.41 - $196.57 $168,216 - $218,389	1,111 Added 2.42%	47,017 $9 Million
Q3 2023 Nov 14, 2023	BUY	$170.77 - $211.65 $150,619 - $186,675	882 Added 1.96%	45,906 $8.13 Million
Q2 2023 Aug 14, 2023	SELL	$185.01 - $212.05 $130,432 - $149,495	-705 Reduced 1.54%	45,024 $8.55 Million
Q1 2023 May 15, 2023	BUY	$182.66 - $235.53 $93,339 - $120,355	511 Added 1.13%	45,729 $9.16 Million
Q4 2022 Feb 21, 2023	BUY	$185.53 - $241.31 $173,285 - $225,383	934 Added 2.11%	45,218 $10.7 Million
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $187,306 - $313,664	1,352 Added 3.15%	44,284 $8.86 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $33,597 - $47,231	-279 Reduced 0.65%	42,932 $6.26 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $12,209 - $16,695	96 Added 0.22%	43,211 $7.06 Million
Q4 2021 Feb 11, 2022	SELL	$159.56 - $209.29 $1.67 Million - $2.19 Million	-10,478 Reduced 19.55%	43,115 $7.31 Million
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $12,863 - $17,689	100 Added 0.19%	53,593 $9.09 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $1.29 Million - $1.79 Million	10,198 Added 23.55%	53,493 $7.55 Million
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $103,540 - $123,774	-842 Reduced 1.91%	43,295 $5.63 Million
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $1.29 Million - $1.76 Million	-10,610 Reduced 19.38%	44,137 $6.43 Million
Q2 2020 Aug 11, 2020	SELL	$104.21 - $156.44 $162,150 - $243,420	-1,556 Reduced 2.76%	54,747 $8.11 Million
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $267,720 - $385,221	-2,875 Reduced 4.86%	56,303 $6.13 Million
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $7,674 - $12,795	103 Added 0.17%	59,178 $6.82 Million
Q3 2019 Nov 14, 2019	SELL	$70.9 - $87.82 $227,801 - $282,165	-3,213 Reduced 5.16%	59,075 $4.75 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $277,599 - $391,109	4,215 Added 7.26%	62,288 $4.52 Million
Q1 2019 May 15, 2019	BUY	$72.76 - $93.45 $16,007 - $20,559	220 Added 0.38%	58,073 $5.43 Million
Q4 2018 Feb 15, 2019	BUY	$62.67 - $88.33 $27,449 - $38,688	438 Added 0.76%	57,853 $4.22 Million
Q3 2018 Nov 15, 2018	BUY	$87.52 - $122.67 $68,615 - $96,173	784 Added 1.38%	57,415 $5.03 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $1.21 Million - $1.48 Million	13,747 Added 32.06%	56,631 $5.58 Million
Q1 2018 May 11, 2018	BUY	$115.92 - $148.54 $226,971 - $290,841	1,958 Added 4.78%	42,884 $5.11 Million
Q4 2017 Feb 15, 2018	BUY	$114.49 - $139.98 $3.2 Million - $3.91 Million	27,914 Added 214.53%	40,926 $5.2 Million
Q3 2017 Nov 08, 2017	BUY	$72.53 - $118.27 $943,760 - $1.54 Million	13,012	13,012 $1.53 Million

Others Institutions Holding ALNY

# of Institutions

614

Shares Held

108M

Call Options Held

2.33M

Put Options Held

2.17M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Alnylam Pharmaceuticals, Inc. Transaction History